GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inhibrx Biosciences Inc (NAS:INBX) » Definitions » Beneish M-Score

INBX (Inhibrx Biosciences) Beneish M-Score : 0.00 (As of Mar. 20, 2025)


View and export this data going back to 2024. Start your Free Trial

What is Inhibrx Biosciences Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Inhibrx Biosciences's Beneish M-Score or its related term are showing as below:

During the past 3 years, the highest Beneish M-Score of Inhibrx Biosciences was 0.00. The lowest was 0.00. And the median was 0.00.


Inhibrx Biosciences Beneish M-Score Historical Data

The historical data trend for Inhibrx Biosciences's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inhibrx Biosciences Beneish M-Score Chart

Inhibrx Biosciences Annual Data
Trend Dec22 Dec23 Dec24
Beneish M-Score
- - -

Inhibrx Biosciences Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only - - - - -

Competitive Comparison of Inhibrx Biosciences's Beneish M-Score

For the Biotechnology subindustry, Inhibrx Biosciences's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inhibrx Biosciences's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inhibrx Biosciences's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Inhibrx Biosciences's Beneish M-Score falls into.



Inhibrx Biosciences Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Inhibrx Biosciences for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 4.8127+0.528 * 1+0.404 * 3.6774+0.892 * 0.1122+0.115 * 0.7809
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 39.8915+4.679 * -0.609376-0.327 * 0.304
=-8.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec24) TTM:Last Year (Dec23) TTM:
Total Receivables was $0.42 Mil.
Revenue was 0.1 + 0 + 0.1 + 0 = $0.20 Mil.
Gross Profit was 0.1 + 0 + 0.1 + 0 = $0.20 Mil.
Total Current Assets was $160.40 Mil.
Total Assets was $180.77 Mil.
Property, Plant and Equipment(Net PPE) was $13.54 Mil.
Depreciation, Depletion and Amortization(DDA) was $2.29 Mil.
Selling, General, & Admin. Expense(SGA) was $126.71 Mil.
Total Current Liabilities was $40.73 Mil.
Long-Term Debt & Capital Lease Obligation was $6.45 Mil.
Net Income was -47.865 + -43.864 + 1858.011 + -49.273 = $1,717.01 Mil.
Non Operating Income was 0.06 + 0.041 + 2021.531 + -0.059 = $2,021.57 Mil.
Cash Flow from Operations was -43.72 + -30.281 + -80.094 + -40.314 = $-194.41 Mil.
Total Receivables was $0.78 Mil.
Revenue was 1.634 + 0.119 + 0.03 + 0 = $1.78 Mil.
Gross Profit was 1.634 + 0.119 + 0.03 + 0 = $1.78 Mil.
Total Current Assets was $295.36 Mil.
Total Assets was $307.89 Mil.
Property, Plant and Equipment(Net PPE) was $9.37 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.19 Mil.
Selling, General, & Admin. Expense(SGA) was $28.32 Mil.
Total Current Liabilities was $56.31 Mil.
Long-Term Debt & Capital Lease Obligation was $208.08 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.42 / 0.2) / (0.778 / 1.783)
=2.1 / 0.436343
=4.8127

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1.783 / 1.783) / (0.2 / 0.2)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (160.398 + 13.538) / 180.767) / (1 - (295.358 + 9.371) / 307.893)
=0.037789 / 0.010276
=3.6774

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=0.2 / 1.783
=0.1122

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1.191 / (1.191 + 9.371)) / (2.285 / (2.285 + 13.538))
=0.112763 / 0.14441
=0.7809

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(126.713 / 0.2) / (28.318 / 1.783)
=633.565 / 15.882221
=39.8915

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((6.453 + 40.73) / 180.767) / ((208.078 + 56.312) / 307.893)
=0.261016 / 0.858707
=0.304

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(1717.009 - 2021.573 - -194.409) / 180.767
=-0.609376

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Inhibrx Biosciences has a M-score of -8.02 suggests that the company is unlikely to be a manipulator.


Inhibrx Biosciences Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Inhibrx Biosciences's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Inhibrx Biosciences Business Description

Traded in Other Exchanges
N/A
Address
11025 N. Torrey Pines Road, Suite 140, La Jolla, CA, USA, 92037
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.